Financhill
Buy
63

LZAGF Quote, Financials, Valuation and Earnings

Last price:
$673.60
Seasonality move :
6.1%
Day range:
$667.58 - $689.14
52-week range:
$560.51 - $755.96
Dividend yield:
0.35%
P/E ratio:
57.13x
P/S ratio:
5.94x
P/B ratio:
4.43x
Volume:
107
Avg. volume:
150
1-year change:
15.27%
Market cap:
$47.3B
Revenue:
$7.5B
EPS (TTM):
$12.01

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Lonza Group AG has -- downside to fair value with a price target of -- per share.

LZAGF vs. S&P 500

  • Over the past 5 trading days, Lonza Group AG has overperformed the S&P 500 by 4.61% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Lonza Group AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Lonza Group AG revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Lonza Group AG reported revenues of --.

Earnings Growth

  • Lonza Group AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lonza Group AG reported earnings per share of --.
Enterprise value:
52.6B
EV / Invested capital:
--
Price / LTM sales:
5.94x
EV / EBIT:
42.42x
EV / Revenue:
6.31x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-136.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
42.42x
Gross Profit (TTM):
$2.7B
Return On Assets:
3.98%
Net Income Margin (TTM):
10.34%
Return On Equity:
8.18%
Return On Invested Capital:
5.53%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-20 2024-12-20 2024-12-20
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets $5.5B $6B $6.3B $5.9B $5.7B
Total Assets $16.5B $17.5B $19.7B $19.9B $23.5B
Current Liabilities $3.4B $2.8B $3B $2.9B $3.9B
Total Liabilities $8.5B $7B $8.1B $9.4B $12.7B
Total Equity $8B $10.6B $11.5B $10.5B $10.9B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-20 2024-12-20 2024-12-20
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
LZAGF
Sector
Market Cap
$47.3B
$28.3M
Price % of 52-Week High
89.11%
51.3%
Dividend Yield
0.35%
0%
Shareholder Yield
2.28%
-1.42%
1-Year Price Total Return
15.27%
-17.78%
Beta (5-Year)
1.145
0.516
Dividend yield:
0.35%
Annualized payout:
$4.41
Payout ratio:
-39.15%
Growth streak:
2 years

Technicals

8-day SMA
Buy
Level $662.48
200-day SMA
Sell
Level $683.71
Bollinger Bands (100)
Sell
Level 664.71 - 710.51
Chaikin Money Flow
Sell
Level -83K
20-day SMA
Buy
Level $673.09
Relative Strength Index (RSI14)
Buy
Level 50.10
ADX Line
Sell
Level 24.87
Williams %R
Neutral
Level -48.0967
50-day SMA
Sell
Level $680.93
MACD (12, 26)
Sell
Level -4.84
25-day Aroon Oscillator
Sell
Level -24
On Balance Volume
Neutral
Level 218.1K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (3.3176)
Buy
CA Score (Annual)
Level (-0.0795)
Buy
Beneish M-Score (Annual)
Level (-2.7761)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-0.819)
Buy
Piotroski F Score (Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Stock Forecast FAQ

In the current month, LZAGF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LZAGF average analyst price target in the past 3 months is --.

  • Where Will Lonza Group AG Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Lonza Group AG share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Lonza Group AG?

    Analysts are divided on their view about Lonza Group AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lonza Group AG is a Sell and believe this share price will rise from its current level to --.

  • What Is Lonza Group AG's Price Target?

    The price target for Lonza Group AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is LZAGF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Lonza Group AG is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of LZAGF?

    You can purchase shares of Lonza Group AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lonza Group AG shares.

  • What Is The Lonza Group AG Share Price Today?

    Lonza Group AG was last trading at $673.60 per share. This represents the most recent stock quote for Lonza Group AG. Yesterday, Lonza Group AG closed at $673.60 per share.

  • How To Buy Lonza Group AG Stock Online?

    In order to purchase Lonza Group AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Bloom Energy The Best Stock to Buy Now?
Is Bloom Energy The Best Stock to Buy Now?

Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…

Is Berkshire Hathaway Stock Undervalued?
Is Berkshire Hathaway Stock Undervalued?

Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…

Is Oracle Stock Undervalued?
Is Oracle Stock Undervalued?

Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…

Stock Ideas

Buy
54
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
57
Is GOOG Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 38x

Alerts

Sell
1
LW alert for Dec 20

Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.

Buy
54
BMRN alert for Dec 20

BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.

Buy
82
RKLB alert for Dec 20

Rocket Lab Corp. [RKLB] is up 17.72% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock